Search academic texts

Information × Registration Number 0216U002857, 0116U007325 , R & D reports Title Landomycin A - novel medicine for chemotherapy of drug-resistant tumors: production, preclinical studies, marketing popup.stage_title Head Stoika Rostyslav Stepanovych, Registration Date 15-12-2016 Organization Institute of Cell Biology NAS of Ukraine popup.description2 A pre-clinical study of the therapeutic effects of promising antitumor antibiotic landomycin A towards experimental models of melanoma B16 and its B16/adr doxorubicin-resistant subline in mice have been carried out. It was demonstrated that landomycin A shows 2-fold higher therapeutic activity towards murine B16 melanoma compared with anticancer drug doxorubicin, and well as possesses much lower myelo- and nephrotoxicity. Potential molecular target of landomycin A - NADP dehydrogenase NQO2, which is responsible for specific induction of oxidative stress in cancer cells by the action of the drug, was identified during fulfillment of this project. The obtained results indicate on a great promise of landomycin A application as a second-line defense drug in treatment of drug-resistant tumor in clinics. Product Description popup.authors Панчук Ростислав Русланович popup.nrat_date 2020-04-02 Close